AR117920A1 - Inhibidores de la replicación del virus de la inmunodeficiencia humana - Google Patents

Inhibidores de la replicación del virus de la inmunodeficiencia humana

Info

Publication number
AR117920A1
AR117920A1 ARP200100242A ARP200100242A AR117920A1 AR 117920 A1 AR117920 A1 AR 117920A1 AR P200100242 A ARP200100242 A AR P200100242A AR P200100242 A ARP200100242 A AR P200100242A AR 117920 A1 AR117920 A1 AR 117920A1
Authority
AR
Argentina
Prior art keywords
immunodeficiency virus
human immunodeficiency
virus replication
replication inhibitors
inhibitors
Prior art date
Application number
ARP200100242A
Other languages
English (en)
Spanish (es)
Original Assignee
VIIV HEALTHCARE UK Nº 5 LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIIV HEALTHCARE UK Nº 5 LTD filed Critical VIIV HEALTHCARE UK Nº 5 LTD
Publication of AR117920A1 publication Critical patent/AR117920A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP200100242A 2019-02-01 2020-01-30 Inhibidores de la replicación del virus de la inmunodeficiencia humana AR117920A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962799800P 2019-02-01 2019-02-01

Publications (1)

Publication Number Publication Date
AR117920A1 true AR117920A1 (es) 2021-09-01

Family

ID=69528890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100242A AR117920A1 (es) 2019-02-01 2020-01-30 Inhibidores de la replicación del virus de la inmunodeficiencia humana

Country Status (9)

Country Link
US (1) US20220105096A1 (https=)
EP (1) EP3917930B1 (https=)
JP (1) JP2022523726A (https=)
AR (1) AR117920A1 (https=)
ES (1) ES2941240T3 (https=)
PT (1) PT3917930T (https=)
TW (1) TW202045502A (https=)
UY (1) UY38559A (https=)
WO (1) WO2020157692A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004593A (es) 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
LT3986561T (lt) * 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
EP3060554A1 (en) 2013-10-24 2016-08-31 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112017022605A2 (pt) 2015-04-23 2018-07-17 Viiv Healthcare Uk No 5 Ltd ?composto, composição, e, método para tratamento de infecção por hiv?.
CN107995910A (zh) 2015-04-23 2018-05-04 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
PT3917930T (pt) 2023-03-30
EP3917930B1 (en) 2023-03-01
US20220105096A1 (en) 2022-04-07
TW202045502A (zh) 2020-12-16
UY38559A (es) 2020-07-31
JP2022523726A (ja) 2022-04-26
EP3917930A1 (en) 2021-12-08
WO2020157692A1 (en) 2020-08-06
ES2941240T3 (es) 2023-05-19

Similar Documents

Publication Publication Date Title
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
NI202000092A (es) Compuestos
CO2021000078A2 (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR119672A1 (es) Inhibidor de 15-pgdh
EA202193015A1 (ru) Ингибиторы cdk
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
CL2022000725A1 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CY1126071T1 (el) Φαρμακευτικα σκευασματα αναλογων κυκλοσπορινης
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
AR110770A1 (es) Moduladores del canal de potasio
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2023015440A (es) Compuesto de sulfoximina y uso del mismo.
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal